Premium
Novel gallium(III) complexes as potential pet imaging agents for probing multidrug resistance ( MDR1 ) P‐glycoprotein (PGP) transport activity: Effect of MDR reversal agents
Author(s) -
Sharma V.,
Dahlheimer J.,
PiwnicaWorms D.
Publication year - 2001
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.2580440126
Subject(s) - p glycoprotein , efflux , chemistry , multiple drug resistance , in vivo , pet imaging , pharmacology , positron emission tomography , nuclear medicine , biochemistry , medicine , biology , microbiology and biotechnology , antibiotics
Evaluation of multidrug resistance ( MDR1 ) P‐glycoprotein (Pgp)‐mediated efflux transport is one potentially important marker in guiding chemotherapeutic treatment in cancer patients. Therefore, methods have been sought [1] to noninvasively image Pgp transport function in vivo [2–9]. In addition to existing SPECT radiotracers for probing Pgp transport activity, non‐metabolized PET agents that offer inherently enhanced spatial resolution and quantification capabilities would enable quantitative noninvasive assessment of chemotherapeutic regimens as well as MDR gene therapy. Thus, organic scaffolds capable of accommodating PET isotopes to generate stable radiopharmaceuticals are desired for functional imaging of MDR1 Pgp‐mediated transport activity.